Remove Heart Transplant Remove Outpatient Remove Technology
article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. Across all patients there was a reduction in cardiac death equivalents and major adverse cardiac and cerebrovascular events.

CMS 111
article thumbnail

V-Wave to Present Late-Breaking Data from Pivotal RELIEVE-HF Study at American College of Cardiology Annual Scientific Session and Expo

DAIC

The primary effectiveness endpoint was a composite of death, heart transplant/left ventricular assist device (LVAD) implantation, HF hospitalization, outpatient HF worsening, and quality of life. and worldwide," said Neal Eigler, M.D. , CEO of V-Wave.